Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)

NCT03064126 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT03064126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03064126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RANGER II SFA: A 3:1 Randomized Trial Comparing the Boston Scientific RANGER™ Paclitaxel Coated Balloon vs Standard Balloon Angioplasty for the Treatment of Superficial Femoral Arteries (SFA) and Proximal Popliteal Arteries (PPA)
Lead sponsor
Boston Scientific Corporation
Phase
Phase 3
Overall status
Completed
Start date
March 2, 2017
Completion date
October 25, 2023
Enrollment
440 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

artery diseases, peripheral, atherosclerosis, occlusive arterial disease, peripheral artery disease, plaque, atherosclerotic